WALTHAM, Mass., May 10, 2017 -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 24, 2017 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of AMAG’s management team and industry experts will provide updates on the Company’s pipeline and commercial programs. In-person attendance requires advanced registration. Please email [email protected] for further information.
A live webcast of the event will be accessible through the Investors section of the company’s website at www.amagpharma.com. A replay of the webcast will also be available and archived on the site.
About AMAG
AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our currently marketed products support the health of patients in the areas of maternal and women's health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit www.amagpharma.com.
AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc. and CBR® is a registered trademark of CBR Systems, Inc.
AMAG Pharmaceuticals Contact: Christi Waarich Associate Director, Investor Relations 617-498-7638


Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Washington Post Publisher Will Lewis Steps Down After Layoffs
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 



